# OnCo record nct07173751 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07173751/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07173751", "NCT07173751" ;
  schema:name "ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer"@en ;
  schema:alternateName "ROSETTA Breast-01"@en ;
  schema:description "A phase 3 trial of PM8002, Gemcitabine, Carboplatin and Eribulin in triple-negative breast cancer, run by BioNTech SE, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07173751/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07173751> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2025-10-30" ;
  onco:cancers <https://onco.cc/cancers/tnbc/> ;
  onco:drugs <https://onco.cc/drugs/pm8002/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/eribulin/> ;
  onco:companies <https://onco.cc/companies/biontech/>, <https://onco.cc/companies/bms/> .